Business context and reporting period
Filing identity discrepancy: The supplied filing is GlycoMimetics, Inc.’s Form 10-Q for the quarter ended March 31, 2014; it does not identify Crescent BioPharma, Inc. as the registrant. Confirm that this is the intended filing before relying on the summary.
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates. Pfizer holds worldwide rights to lead candidate GMI-1070; the company retains rights to its other candidates, including GMI-1271. The filing is unaudited and describes the company as a development-stage enterprise.
Financial results and position
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Revenue | $0 | $3.81 million |
| Research and development expense | $3.88 million | $2.74 million |
| General and administrative expense | $1.22 million | $0.61 million |
| Operating loss (income) | $(5.11) million | $0.46 million |
| Net loss (income) | $(5.10) million | $0.46 million |
| Net loss (income) per share, diluted | $(0.30) | $0.04 |
| Net cash used in operations | $2.59 million | $3.88 million |
No product revenue was reported. The 2013 revenue was the final recognition of the deferred Pfizer upfront payment; it had been fully recognized by March 31, 2013. Product margins are not meaningful because the company had no product sales.
At March 31, 2014, cash and cash equivalents were $56.97 million, total current assets $57.69 million, total current liabilities $2.64 million, total liabilities $2.71 million, and stockholders’ equity $55.35 million. The balance sheet reports no debt outstanding. Q1 investing cash use was $13,920; financing cash inflow was $57.26 million, principally IPO proceeds. The accumulated development-stage deficit was $68.38 million.
Material changes versus the prior comparable period
- Revenue fell by $3.81 million to zero as Pfizer upfront-payment revenue recognition ended.
- R&D expense rose 42% to $3.88 million, primarily due to GMI-1271 manufacturing and process-development work ahead of a planned IND filing.
- G&A expense increased 102% to $1.22 million, reflecting public-company costs, professional fees, insurance, personnel, and increased stock-based compensation.
- Net results shifted from $0.46 million income to a $5.10 million loss; management attributed the year-over-year revenue change to the completed Pfizer revenue recognition and higher operating expenses.
- The January 2014 IPO raised approximately $57.3 million net. Preferred shares converted into common shares at IPO closing; common shares outstanding were 18,781,952 at March 31, 2014.
Outlook, commentary, and risks
- Management expected existing cash, excluding potential Pfizer milestone payments, to fund operations and capital needs for at least 12 months from March 31, 2014. It cautioned that estimates depend on assumptions and cash could be used sooner.
- The company planned to prepare and initiate Phase 1 and Phase 1/2 trials of GMI-1271 in 2014 and expected R&D and public-company costs to increase. The filing describes an IND filing in the first half of 2014 as a plan, not a completed milestone.
- Pfizer had advised the joint steering committee of its intent to begin enrolling a Phase 3 GMI-1070 trial in the second half of 2014, subject to Pfizer governance approval. A $35 million milestone could be payable upon first-patient dosing; the company expected a $15 million advance in Q2 2014, also conditional. Neither payment had been earned or recognized as of March 31.
- The company has no approved products and expects continuing losses. Future financing may be needed; financing may be unavailable or dilute shareholders, restrict operations, or require the company to relinquish candidate rights.
- Principal risks include clinical and regulatory failure or delay, patient-enrollment and manufacturing constraints, dependence on Pfizer for GMI-1070, competition, intellectual-property protection, and limited funding beyond available cash and contingent collaboration payments. Pfizer may terminate its agreement.
- The filing reports no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of quarter-end. A 100-basis-point interest-rate change was not expected to materially affect the value of cash equivalents.
Important facts for investors to verify
- Confirm the issuer: the filing names GlycoMimetics, Inc., not Crescent BioPharma, Inc.
- Check subsequent filings for whether Pfizer initiated the GMI-1070 Phase 3 trial and whether any advance or milestone payment was received.
- Verify the timing and outcome of the GMI-1271 IND filing and planned clinical trials, along with clinical supply availability.
- Assess cash burn, updated cash runway, and financing needs against the filing’s conditional 12-month runway estimate.
- Review subsequent disclosures on clinical results, regulatory developments, collaboration status, and share dilution.